gliclazide has been researched along with Colitis Gravis in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ulcerative Colitis is a universal autoimmune disease with high incidence rates worldwide." | 1.56 | Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARγ, NF-κB and MAPK signaling pathways. ( Arafa, EA; Mohamed, WR; Omar, HA; Zaher, DM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arafa, EA | 1 |
| Mohamed, WR | 1 |
| Zaher, DM | 1 |
| Omar, HA | 1 |
1 other study available for gliclazide and Colitis Gravis
| Article | Year |
|---|---|
Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARγ, NF-κB and MAPK signaling pathways.
Topics: Acetic Acid; Animals; Apoptosis; Body Weight; Caspase 3; Caspase Inhibitors; Colitis, Ulcerative; Co | 2020 |